Did you mean 9,10 90 9?
Displaying drugs 1426 - 1450 of 2248 in total
WU-NK-101
WU-NK-101 is an allogeneic CD3-depleted, CD56-enriched activated natural killer-cell product
Investigational
AOC 1001
AOC 1001 is an antibody oligonucleotide conjugate (AOC), comprised of a human transferrin receptor 1 (TfR1) targeting, effector function null, humanized IgG1 antibody (AV01mAb) conjugated to one small interfering RNA (siRNA).
Investigational
CYNK-101
CYNK-101 is an allogeneic human placental hematopoietic stem cell-derived natural killer (NK) cell therapy product that is genetically modified to express a variant of CD16 (CD16VP).
Investigational
CT-001
Investigational
ONCOS-102
Investigational
Dihomo-gamma-linolenic acid
A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5.
Investigational
Nutraceutical
Gpi-1046
Experimental
AGI-1096
AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common in chronic organ transplant rejection.
Investigational
XMT-1001
XMT-1001 is a polymer-based prodrug of camptothecin (CPT), a well-characterized topoisomerase I inhibitor with potent anti-tumor activity. It is a water-soluble macromolecular conjugate of camptothecin (CPT). In this novel CPT pro-drug, CPT is conjugated with a 70 kDa biodegradable hydrophilic polyacetal, poly (1-hydroxymethylene hydroxylmethylformal). XMT-1001 has demonstrated an improved therapeutic...
Investigational
CTS-1027
CTS-1027 has been used in trials studying the treatment of Hepatitis C and Chronic Hepatitis C Virus Infection.
Experimental
Investigational
CTT-1057
CTT-1057 is under investigation in clinical trial NCT03427476 (CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma).
Investigational
TERN-101
TERN-101 is under investigation in clinical trial NCT04328077 (LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH)).
Investigational
TALL-104
Investigational
PPI-1040
Investigational
NP-10679
Investigational
RBIO-101
RBIO-101 is a recombinant adeno-associated virus vector encoding human CYP4V2 protein.
Investigational
ORY-1001
Investigational
Amrubicin
Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. Since January...
Investigational
Matched Iupac: … (7S,9S)-9-acetyl-9-amino-7-{[(2S,4S,5R)-4,5-dihydroxyoxan-2-yl]oxy}-6,11-dihydroxy-5,7,8,9,10,12-hexahydrotetracene …
INKP-102
INKP-102 is the next generation sodium phosphate tablet designed to aid bowl preparation before colonoscopy.
Investigational
ISS-1018
ISS 1018 is a short, synthetic, unmethylated CpG oligodeoxynucleotide (CpG ODN) with immunostimulatory activity. ISS 1018 signals through Toll-like receptor 9 (TLR9) to induce the production of immunoglobulin by B cells and interferon (IFN) -alpha, IFN-beta, interleukin-12 (IL-12), and tumor necrosis factor - alpha (TNF-alpha) by plasmacytoid dendritic cells (pDC)....
Investigational
Matched Description: … ISS 1018 signals through Toll-like receptor 9 (TLR9) to induce the production of immunoglobulin by B …
PPI-1019
Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.
Investigational
ORE-1001
ORE1001 has been used in trials studying the treatment of Mild to Moderate Ulcerative Colitis. It is an ACE2 inhibitor.
Investigational
Displaying drugs 1426 - 1450 of 2248 in total